Cargando…
Effective holistic characterization of small molecule effects using heterogeneous biological networks
The two most common reasons for attrition in therapeutic clinical trials are efficacy and safety. We integrated heterogeneous data to create a human interactome network to comprehensively describe drug behavior in biological systems, with the goal of accurate therapeutic candidate generation. The Co...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169664/ https://www.ncbi.nlm.nih.gov/pubmed/37180722 http://dx.doi.org/10.3389/fphar.2023.1113007 |
_version_ | 1785039088543334400 |
---|---|
author | Mangione, William Falls, Zackary Samudrala, Ram |
author_facet | Mangione, William Falls, Zackary Samudrala, Ram |
author_sort | Mangione, William |
collection | PubMed |
description | The two most common reasons for attrition in therapeutic clinical trials are efficacy and safety. We integrated heterogeneous data to create a human interactome network to comprehensively describe drug behavior in biological systems, with the goal of accurate therapeutic candidate generation. The Computational Analysis of Novel Drug Opportunities (CANDO) platform for shotgun multiscale therapeutic discovery, repurposing, and design was enhanced by integrating drug side effects, protein pathways, protein-protein interactions, protein-disease associations, and the Gene Ontology, and complemented with its existing drug/compound, protein, and indication libraries. These integrated networks were reduced to a “multiscale interactomic signature” for each compound that describe its functional behavior as vectors of real values. These signatures are then used for relating compounds to each other with the hypothesis that similar signatures yield similar behavior. Our results indicated that there is significant biological information captured within our networks (particularly via side effects) which enhance the performance of our platform, as evaluated by performing all-against-all leave-one-out drug-indication association benchmarking as well as generating novel drug candidates for colon cancer and migraine disorders corroborated via literature search. Further, drug impacts on pathways derived from computed compound-protein interaction scores served as the features for a random forest machine learning model trained to predict drug-indication associations, with applications to mental disorders and cancer metastasis highlighted. This interactomic pipeline highlights the ability of Computational Analysis of Novel Drug Opportunities to accurately relate drugs in a multitarget and multiscale context, particularly for generating putative drug candidates using the information gleaned from indirect data such as side effect profiles and protein pathway information. |
format | Online Article Text |
id | pubmed-10169664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101696642023-05-11 Effective holistic characterization of small molecule effects using heterogeneous biological networks Mangione, William Falls, Zackary Samudrala, Ram Front Pharmacol Pharmacology The two most common reasons for attrition in therapeutic clinical trials are efficacy and safety. We integrated heterogeneous data to create a human interactome network to comprehensively describe drug behavior in biological systems, with the goal of accurate therapeutic candidate generation. The Computational Analysis of Novel Drug Opportunities (CANDO) platform for shotgun multiscale therapeutic discovery, repurposing, and design was enhanced by integrating drug side effects, protein pathways, protein-protein interactions, protein-disease associations, and the Gene Ontology, and complemented with its existing drug/compound, protein, and indication libraries. These integrated networks were reduced to a “multiscale interactomic signature” for each compound that describe its functional behavior as vectors of real values. These signatures are then used for relating compounds to each other with the hypothesis that similar signatures yield similar behavior. Our results indicated that there is significant biological information captured within our networks (particularly via side effects) which enhance the performance of our platform, as evaluated by performing all-against-all leave-one-out drug-indication association benchmarking as well as generating novel drug candidates for colon cancer and migraine disorders corroborated via literature search. Further, drug impacts on pathways derived from computed compound-protein interaction scores served as the features for a random forest machine learning model trained to predict drug-indication associations, with applications to mental disorders and cancer metastasis highlighted. This interactomic pipeline highlights the ability of Computational Analysis of Novel Drug Opportunities to accurately relate drugs in a multitarget and multiscale context, particularly for generating putative drug candidates using the information gleaned from indirect data such as side effect profiles and protein pathway information. Frontiers Media S.A. 2023-04-26 /pmc/articles/PMC10169664/ /pubmed/37180722 http://dx.doi.org/10.3389/fphar.2023.1113007 Text en Copyright © 2023 Mangione, Falls and Samudrala. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Mangione, William Falls, Zackary Samudrala, Ram Effective holistic characterization of small molecule effects using heterogeneous biological networks |
title | Effective holistic characterization of small molecule effects using heterogeneous biological networks |
title_full | Effective holistic characterization of small molecule effects using heterogeneous biological networks |
title_fullStr | Effective holistic characterization of small molecule effects using heterogeneous biological networks |
title_full_unstemmed | Effective holistic characterization of small molecule effects using heterogeneous biological networks |
title_short | Effective holistic characterization of small molecule effects using heterogeneous biological networks |
title_sort | effective holistic characterization of small molecule effects using heterogeneous biological networks |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169664/ https://www.ncbi.nlm.nih.gov/pubmed/37180722 http://dx.doi.org/10.3389/fphar.2023.1113007 |
work_keys_str_mv | AT mangionewilliam effectiveholisticcharacterizationofsmallmoleculeeffectsusingheterogeneousbiologicalnetworks AT fallszackary effectiveholisticcharacterizationofsmallmoleculeeffectsusingheterogeneousbiologicalnetworks AT samudralaram effectiveholisticcharacterizationofsmallmoleculeeffectsusingheterogeneousbiologicalnetworks |